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1116The Incidence of Trilateral Retinoblastoma:
A Systematic Review and Meta-AnalysisMARCUS C. DE JONG, WIJNANDA A. KORS, PIM DE GRAAF, JONAS A. CASTELIJNS, ANNETTE C. MOLL, AND
TERO KIVELA¨ PURPOSE: To estimate the incidence of trilateral reti-
noblastoma in patients with retinoblastoma.
 DESIGN: Systematic review and meta-analysis.
 METHODS: We searchedMedline and Embase for scien-
tific literature published between January 1966 and July
2015 that assessed trilateral retinoblastoma incidence.
We used a random-effects model for the statistical ana-
lyses.
 RESULTS: We included 23 retinoblastoma cohorts
from 26 studies. For patients with bilateral retino-
blastoma the unadjusted chance of developing trilat-
eral retinoblastoma across all cohorts was 5.3%
(95% confidence interval [CI]: 3.3%–7.7%); the
chance of pineal trilateral retinoblastoma was 4.2%
(95% CI: 2.6%–6.2%) and the chance of nonpineal
trilateral retinoblastoma was 0.8% (95% CI: 0.4%–
1.3%). In patients with hereditary retinoblastoma
(all bilateral cases, and the unilateral cases with a
family history or germline RB1 mutation) we found
a trilateral retinoblastoma incidence of 4.1% (95%
CI: 1.9%–7.1%) and a pineal trilateral retinoblas-
toma incidence of 3.7% (95% CI: 1.8%–6.2%). To
reduce the risk of overestimation bias we restricted
analysis to retinoblastoma cohorts with a minimum
size of 100 patients, resulting in adjusted incidences
of 3.8% (95% CI: 2.4%–5.4%), 2.9% (95% CI:
1.9%–4.2%), and 0.7% (95% CI: 0.3%–1.2%) for
any, pineal, and nonpineal trilateral retinoblastoma,
respectively, among patients with bilateral retino-
blastoma. Among hereditary retinoblastoma we found
an adjusted trilateral retinoblastoma incidence of
3.5% (95% CI: 1.2%–6.7%) and a pineal trilateral
retinoblastoma incidence of 3.2% (95% CI: 1.4%–
5.6%).
 CONCLUSION: The estimated incidence of trilateral
retinoblastoma is lower than what is reported in
previous literature, especially after exclusion of smallupplemental Material available at AJO.com.
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NTIL THE AGE OF ABOUT 7 YEARS PATIENTS WITH
hereditary retinoblastoma are at risk of having an
intracranial midline primitive neuroectodermal
tumor diagnosed, and among patients diagnosed since
1995 more than 95% have developed trilateral retinoblas-
toma before the age of 5 years.1–3 In histopathologic
analysis these tumors look similar to corresponding retinal
tumors. When unilateral or bilateral retinoblastoma and
an intracranial midline primitive neuroectodermal tumor
both occur in a patient, this is referred to as trilateral
retinoblastoma, which can be found in the pineal gland
(pineal trilateral retinoblastoma) in about three-quarters
of cases; in the remaining patients it develops in other
midline brain regions (nonpineal trilateral retinoblastoma),
usually the suprasellar and parasellar region, although other
brain regions have been reported also.3–5
In a recent meta-analysis we showed that survival has
improved considerably in the last 2 decades, from hardly
any to almost half of all patients.3 Favorable survival after
pineal trilateral retinoblastoma depended strongly on early
detection and small tumor size. The improved survival after
trilateral retinoblastoma was highly associated with the use
of (improved) chemotherapy regimens, especially high-
dose chemotherapy with stem cell rescue.3
Previous radiotherapy for retinoblastoma, especially
before the age of 12 months, has been associated with a
potentially higher incidence of pineal trilateral retinoblas-
toma in patients with hereditary retinoblastoma, even
though the pineal gland is usually not (directly) within
the field of radiation.6 Whether previous systemic chemo-
therapy is protective of developing trilateral retinoblas-
toma is still being debated.7–10
There have been numerous reports on trilateral
retinoblastoma incidence, but these studies are
quite heterogeneous. Some are referral-based, others
population-based. The only previously published study
summarizing incidence data across studies reported an
incidence of 5%–15% among patients with bilateral
retinoblastoma.2
The objective of this study is to provide an overview
of, to critically analyze, and to provide pooled summary
estimates of published incidence data for pineal and
nonpineal trilateral retinoblastoma.0002-9394/$36.00
http://dx.doi.org/10.1016/j.ajo.2015.09.009
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FIGURE 1. Trilateral retinoblastoma incidence vs the size of the cohorts of patients with unilateral or bilateral retinoblastoma. The
estimated curve in this figure is an S-curve with a fit of R2[0.44, P[ .0027.METHODS
WE PERFORMED THIS SYSTEMATIC REVIEW AND META-
analysis according to the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) state-
ment.11,12
 SEARCH STRATEGY: We searched Medline (PubMed)
and Embase for English, Dutch, and German literature
published from January 1, 1966 through July 15, 2015, eval-
uating trilateral retinoblastoma cases. We also considered
alternatively found studies for inclusion (eg, through
checking references in included studies). The search was
similar to the search we used in our systematic review
and meta-analysis on survival of patients with trilateral
retinoblastoma.3 To ensure a sensitive search, we included
only keywords corresponding to the target condition
(including retinoblastoma, pineoblastoma, pineal, supra-
sellar, parasellar, sellar, ectopic, and brain), without any
delimiters. For the detailed search see Supplemental
Table 1 (available at AJO.com).
 STUDY SELECTION AND DATA EXTRACTION: Two au-
thors (M.C.J. and A.C.M.) independently reviewed article
titles and abstracts for eligibility. Discrepancies were
resolved by consensus. Subsequently the same 2 authors
independently reviewed eligible full-text articles for inclu-
sion in the systematic review andmeta-analysis. Again, dis-
crepancies were solved by consensus.VOL. 160, NO. 6 THE INCIDENCE OF TRILATEWe included studies in the systematic review and meta-
analysis if (1) the study mentioned the number of patients
with trilateral retinoblastoma (can also be 0, as long as au-
thors mentioned evaluating for trilateral retinoblastoma
cases), if (2) articles reported details and size of the retino-
blastoma cohort in which patients with trilateral retino-
blastoma were seen (eg, number of patients with
trilateral retinoblastoma diagnosed in a cohort of patients
with retinoblastoma during a certain period), and if (3)
the full-text article could be obtained. We excluded
studies from the systematic review if (1) the article was a
review or meta-analysis, and if (2) studies included over-
lapping incidence data. Two authors (M.C.J. and
W.A.K.) independently extracted incidence data. Dis-
crepancies were resolved by consensus. We have defined
hereditary retinoblastoma as patients with bilateral reti-
noblastoma, known familial retinoblastoma, or a detected
germline mutation in RB1.
 DATASYNTHESIS ANDSTATISTICALANALYSIS: Ideally,
we would present the cumulative incidence of trilateral
retinoblastoma until a certain age (eg, up to 5 years) in
comparable retinoblastoma cohorts; however, most studies
only provided the total number of patients with retinoblas-
toma and the number of trilateral retinoblastoma cases they
found in their cohort. Therefore we are restricted to the
calculation of a percentage of cases that developed trilat-
eral retinoblastoma divided by total retinoblastoma cohort
from a certain time period. This method unfortunately does1117RAL RETINOBLASTOMA
FIGURE 2. Flow chart of the total number of articles found with PubMed and Embase and subsequent inclusion and exclusion of
articles, leading to the number of included articles and retinoblastoma cohorts that contained information on trilateral retinoblastoma
incidence.not take into account the effect of patients lost to follow-up
(ie, assuming that of all patients with retinoblastoma it is
unequivocally known whether they developed trilateral
retinoblastoma or not).
In addition to performing unadjusted analysis, we calcu-
lated adjusted estimates by including cohorts of at least 100
patients with retinoblastoma, to prevent overestimation
bias. Most small cohorts published specifically after
encountering at least 1 trilateral retinoblastoma and thus
led to a report irrespective of how many patients without
trilateral retinoblastoma had been seen (ie, an arbitrary
cohort of patients with retinoblastoma with a certain start
and end date will have been constructed around the pa-
tient(s) with trilateral retinoblastoma that were encoun-
tered). The limit of 100 patients was based on visual
evaluation of a plot of the incidence of trilateral retinoblas-
toma against the total sample size across studies (Figure 1).
Typically, an unselected patient population contains 40%
of bilateral retinoblastoma, and thus we considered also a
cohort of at least 40 bilateral retinoblastomas to be large
enough to guard for overestimation bias.
To assess the extent of this bias we compared data from
developed vs developing countries, as one would expect
follow-up to be more complete in developed countries
(ie, higher chance to find a trilateral retinoblastoma).
This might lead to an underestimation of trilateral retino-1118 AMERICAN JOURNAL OFblastoma incidence in the developing countries. Pooling
data from different retinoblastoma cohorts also assumes
comparability of these cohorts.
To evaluate changes in trilateral retinoblastoma inci-
dence over time we used a cutoff at the year 1995. We
chose this cutoff because around (or maybe even before)
1995 treatment of retinoblastoma started to shift from
radiotherapy to chemotherapy.13
We used a random-effects model to calculate summary
estimates of trilateral retinoblastoma incidence.14,15 A
random-effects model is used for meta-analyses to account
for heterogeneity between studies. For each analysis we
calculated I2 to evaluate heterogeneity among included
studies; I2 ranges from 0 to 100% with increasing heteroge-
neity.16 For the random-effects analyses we used MetaXL
(version 2.1; EpiGear, Wilston, Australia) and SAS
(Proc MIXED, version 9.3; SAS, Cary, North Carolina,
USA). The forest plots were created with Illustrator CS6
(Adobe, San Jose, California, USA).
 RISK OF BIAS AND STUDY QUALITY ASSESSMENT: Two
authors (M.C.J. and T.K.) assessed the risk of bias with a
modified checklist that was developed for prevalence
studies by Hoy and associates.17 With the checklist 6 items
that could lead to bias were assessed (Supplemental
Table 2, available at AJO.com).18,19DECEMBER 2015OPHTHALMOLOGY
TABLE 1. Basic Information About the Retinoblastoma Cohorts of All Included Studies That Presented Trilateral Retinoblastoma Incidence Data
Study Inclusion Period Country
Source of
the Data
Type of
Patients
With
Retinoblastoma
Age at
Retinoblastoma
Diagnosis (Months)
Patient
Follow-up
From Retinoblastoma
Diagnosis (Months)
Percentage
of Cohort
With Unilateral
Retinoblastoma
Percentage
of Cohort
With Bilateral
Retinoblastoma
Percentage
of Cohort With
Familial
Retinoblastoma
Study Cohort
(Partly) Overlaps With
Amoaku et al26 1960–1994 United
Kingdom
Population
registry
Any Mean 6, range 0.75–17 64% 36% 38a
Antoneli et al27 1986–2003 Brasil 1 center Any 60% 40%
Azar et al28 1975–2001 Australia 2 centers Any Mean 17.9
(bilateral 22.6,
unilateral 3.5)
60% 40% 11
Bartuma et al29 2001–2011 Sweden 1 center Hereditary Mean 8, range 0–39 Mean 60,
range 13–144
8% 92% 38
Blach et al22 1979–1990 USA 1 center Irradiated Median 7, range <1–60 Median 68,
range 4–153
17% 83% 27
Chantada et al10 1988–2012 Argentina 1 center Bilateral Mean 13.9, range 0–114 Median 115,
range 31–290
100% 14a Moreno et al30
De Ioris et al31 1999–2009 Italy 1 center Any Median 10, range 0.5–73 58% 42% 14
De Potter et al32 1972–1992 United
Kingdom
1 center Any 54% 46% 14
Duncan et al33 1990–1998 USA 2 centers Any Mean 44.8,
range 0–139
>_63% <_37%
Helveston et al34 1967–1987 USA 1 center Any Unilateral 23, bilateral 10b 59% 41%
Imhof et al23 1971–1993 Netherlands 1 center Irradiated Mean 5, range 1–216 Mean 148,
range 48–276
Moll et al6
Jubran et al35 1991–1999 USA 1 center Any
Jurkiewicz et al36 1996–2008 Poland 1 center Any Unilateral median 22,
bilateral median 12
Kingston et al37 1954–1983 United
Kingdom
2 centers Any 31% 69%
Klufas et al24 2006–2010 USA 1 center Treated with
intraarterial
chemotherapy
Median 17.5,
range 8–36
Lim et al38 2001–2009 Malaysia 1 center Any
Lim et al39 1997–2010 Singapore 1 center Any 25.7, SD 19.9
(unilateral mean: 30.2,
SD 21.4, bilateral mean:
15.4, SD 9.6)
Median 36,
range 0–156
69% 31%
Continued on next page
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TABLE 1. Basic Information About the Retinoblastoma Cohorts of All Included Studies That Presented Trilateral Retinoblastoma Incidence Data (Continued )
Study Inclusion Period Country
Source of
the Data
Type of
Patients
With
Retinoblastoma
Age at
Retinoblastoma
Diagnosis (Months)
Patient
Follow-up
From Retinoblastoma
Diagnosis (Months)
Percentage
of Cohort
With Unilateral
Retinoblastoma
Percentage
of Cohort
With Bilateral
Retinoblastoma
Percentage
of Cohort With
Familial
Retinoblastoma
Study Cohort
(Partly) Overlaps With
Lueder et al40 1924–1985 USA 1 center Any 67% 33% 14 Lueder et al41
Lueder et al.41 1924–1989 USA 1 center Any 14 Lueder et al40
Moll et al6 1970–1997 Netherlands Population
registry
Hereditary Imhof et al23
Moreno et al30 2000–2009 Argentina Population
registry
Any Unilateral median 26
(IQR 13–42), bilateral
median 10 (IQR 5–19)
68% 32% Chantada et al10
Popovic et al25 1990–2001 Switzerland 1 center Any 49% 51%
Provenzale et al42 1985–2002 USA 1 center Any 52% 48%
Ramasubramanian
et al8,21
2000–2012 USA 1 center Any Mean 21, median 13,
range 0–91
53% 47% 11
Scott et al43 1970–1990 USA 1 center Any Mean 15.8
(nonhereditary mean 20.5,
hereditary mean 11.7)
52% 48%
Shields et al20 1995–1999 USA 1 center Any Mean 14, median 8,
range 1–87
Mean 33,
range 0–67
48% 52% 18
IQR ¼ interquartile range; SD ¼ standard deviation.
aAs percentage of the patients with bilateral retinoblastoma.
bAge at treatment; unknown if these are means or medians or some other measure.
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RESULTS
WE IDENTIFIED 1865 UNIQUE STUDIES FROM DATABASE
searches. We excluded 1734 articles based on title and ab-
stract (Figure 2). We excluded 105 studies based on the full
text; reasons for exclusion are shown in Figure 2. Twenty-
six studies (3 pairs of studies had overlapping cohorts but
provided different data of interest and were therefore
included; see Table 1) met the inclusion criteria of this sys-
tematic review. Twenty-one studies (20 cohorts) were
included in the meta-analysis. Tables 2 and 3 show the
incidence data as reported in each included study.
 UNADJUSTED ESTIMATES: Twenty-six studies reported
trilateral retinoblastoma incidence in 23 unique cohorts
of patients with retinoblastoma, and in 15 studies (15 co-
horts) bilateral could be distinguished from unilateral reti-
noblastoma (Table 2). Seven studies (6 cohorts) presented
the trilateral retinoblastoma incidence in hereditary reti-
noblastoma, 3 studies (cohorts) reported trilateral retino-
blastoma incidence after external beam irradiation for
retinoblastoma, and 5 studies (cohorts) compared the inci-
dence in patients with retinoblastoma with and without
previous chemotherapy. Forest plots of the included studies
(sorted by the midpoint of the study period) and the sum-
mary estimates are shown in Figure 3.
For unilateral and bilateral retinoblastoma combined,
the unadjusted chance of developing a trilateral retinoblas-
toma across all studies is 2.1% (95% confidence interval
[CI]: 1.4%–2.8%; 18 cohorts), the chance of developing
pineal trilateral retinoblastoma is 1.7% (95% CI: 1.2%–
2.3%; 19 cohorts), and the chance of a nonpineal trilateral
retinoblastoma is 0.4% (95% CI: 0.2%–0.6%; 18 cohorts).
For bilateral retinoblastoma the chance of developing a
trilateral retinoblastoma is 5.3% (95% CI: 3.3%–7.7%;
14 cohorts); restricting calculations to pineal trilateral reti-
noblastoma resulted in an incidence of 4.2% (95% CI:
2.6%–6.2%; 15 cohorts) and restricting to nonpineal trilat-
eral retinoblastoma gave an incidence of 0.8% (95% CI:
0.4%–1.3%; 14 cohorts). In hereditary retinoblastoma we
found a trilateral retinoblastoma incidence of 4.2% (95%
CI: 1.6%–7.7%; 5 cohorts) and a pineal trilateral retino-
blastoma incidence of 3.7% (95% CI: 1.8%–6.2%; 6 co-
horts), and we did not calculate the nonpineal trilateral
retinoblastoma incidence, as there were no cases in 5 reti-
noblastoma cohorts.
 ADJUSTED ESTIMATES: We adjusted for potential over-
estimation bias by restricting the analysis to cohorts that
included at least 100 patients with retinoblastoma
(Figure 1). We found incidences of 1.7% (95% CI: 1.2%–
2.2%; 14 cohorts), 1.4% (95%CI: 1.0%–1.7%; 15 cohorts),
and 0.3% (95%CI: 0.2%–0.6%; 14 cohorts) for any, pineal,
and nonpineal trilateral retinoblastoma, respectively. In
cohorts with only patient with bilateral retinoblastomaVOL. 160, NO. 6 THE INCIDENCE OF TRILATEwe found incidences of 3.8% (95% CI: 2.4%–5.4%; 10 co-
horts), 2.9% (95% CI: 1.9%–4.2%; 11 cohorts) and 0.7%
(95% CI: 0.3%–1.2%; 10 cohorts), respectively. Among
patients with hereditary retinoblastoma we found a trilat-
eral retinoblastoma incidence of 3.5% (95% CI: 1.2%–
6.7%; 4 cohorts) and a pineal trilateral retinoblastoma inci-
dence of 3.2% (95% CI: 1.4%–5.6%; 5 cohorts).
 PERIOD ANALYSIS: To analyze changes over time we
created 2 groups with the year 1995 as the cutoff year
(depending on the midpoint of the study period). Before
the year 1995 unadjusted trilateral retinoblastoma inci-
dence for unilateral and bilateral retinoblastoma combined
was 2.5% (95% CI: 1.5%–3.8%) vs 1.5% (95% CI: 0.9%–
2.2%) from the year 1995 onward (P¼ .24). The incidence
of pineal trilateral retinoblastoma before the year 1995 was
2.2% (95%CI: 1.3%–3.4%) vs 1.2% (95%CI: 0.8%–1.8%)
from 1995 onward (P ¼ .14).
Restricted to patients with bilateral retinoblastoma, the
unadjusted trilateral retinoblastoma incidence was 6.2%
(95% CI: 3.2%–9.9%) before the year 1995 vs 3.7%
(95% CI: 1.4%–6.9%) from the year 1995 onward (P ¼
.44). The incidence of pineal trilateral retinoblastoma
was 5.3% (95% CI: 2.7%–8.8%) before the year 1995 vs
2.9% (95% CI: 1.3%–5.1%) from the year 1995 onward
(P ¼ .38; Figure 3).
 EFFECT OF PREVIOUS THERAPY: Four studies reported
on trilateral retinoblastoma incidence in retinoblastoma
cohorts who underwent previous systemic chemotherapy
(Table 3). In a single-center study with 4 trilateral retino-
blastoma cases an inverse association between chemo-
therapy and the development of pineoblastoma was
reported (P ¼ .014), with an incidence of 0.6% (1/180)
and 8.6% (3/35), respectively, for patients who did and
who did not receive previous chemotherapy for their reti-
noblastoma.8 In a single-center study from the same center,
but different period, 1 pineoblastoma was found in 18 he-
reditary patients with retinoblastoma who did not undergo
chemotherapy, compared to none in 99 patients who did
undergo chemotherapy.20 However, in another single-
center study with 3 trilateral retinoblastomas this associa-
tion was reversed with an incidence of 1.9% (3/159) vs
0.0% (0/38), respectively (P > .99).10
Three studies specifically looked at trilateral retinoblas-
toma incidence in cohorts of patients with retinoblastoma
who underwent external beam radiotherapy (Table 3). In a
single-center study with 4 trilateral retinoblastomas a pi-
neal trilateral retinoblastoma incidence of 1.7% (3/179)
was found in the group of patients with nonirradiated he-
reditary retinoblastoma and an incidence of 2.8% (1/36)
was found in the irradiated group (P ¼ .5).8,21 A single-
center study with 6 trilateral retinoblastomas found that
patients with bilateral retinoblastoma who underwent irra-
diation as treatment for their retinoblastoma had a 6.2%1121RAL RETINOBLASTOMA
TABLE 2. Incidence of Trilateral Retinoblastoma Among Unilateral and Bilateral Retinoblastoma, Bilateral Retinoblastoma, and
Hereditary Retinoblastoma for Studies Included in the Meta-analysis
Study Inclusion Period
Unilateral and Bilateral Retinoblastoma Bilateral Retinoblastoma Hereditary Retinoblastoma
Pineal Nonpineal Pineal Nonpineal Pineal Nonpineal
Amoaku et al26 1960–1994 2.7% (4/146) 0.7% (1/146) 7.7% (4/52) 1.9% (1/52)
Antoneli et al27 1986–2003 0.6% (3/470) 0.2% (1/470) 1.1% (2/186) 0.5% (1/186)
Azar et al28 1975–2001 1.6% (2/123) 0.0% (0/123) 4.1% (2/49) 0.0% (0/49)
De Ioris et al31 1999–2012 2.8% (3/107) 0.0% (0/107) 6.7% (3/49) 0.0% (0/49)
De Potter et al32 1972–1992 2.0% (9/440) 0.7% (3/440) 4.0% (8/202) 1.5% (3/202)
Duncan et al33 1990–1998 0.9% (2/226) 0.0% (0/226) 2.4% (2/85)a 0.0% (0/85)a
Helveston et al34 1967–1987 1.4% (1/74) 0.0% (0/74) 3.3% (1/30) 0.0% (0/30)
Jubran et al35 1991–1999 1.4% (3/207) 0.0% (0/207)
Jurkiewicz et al36 1996–2008 0.5% (1/202) 1.0% (2/202)
Kingston et al37 1954–1983 1.3% (8/630) 0.5% (3/630) 1.9% (8/432) 0.5% (2/432)
Lim et al38 2001–2009 1.4% (2/141) 0.0% (0/141)
Lim et al39 1997–2010 3.9% (2/51) 0.0% (0/51) 12.5% (2/16) 0.0% (0/16)
Lueder et al40 1924–1985 2.3% (3/132) 0.0% (0/132) 6.8% (3/44) 0.0% (0/44) 6.0% (3/50) 0.0% (0/50)
Lueder et al41 1924–1989 2.7% (4/143) 7.1% (4/56)
Moll et al6 1970–1997 5.8% (7/121) 0.0% (0/121)
Moreno et al30 2000–2009 0.7% (3/438) 0.0% (0/438) 2.2% (3/139) 0.0% (0/139)
Popovic et al25 1990–2001 1.8% (4/221) 0.5% (1/221) 3.7% (4/108) 0.9% (1/108)
Provenzale et al42 1985–2002 11.1% (7/63) 1.6% (1/63) 23.3% (7/30) 3.3% (1/30)
Ramasubramanian et al8,21 2000–2012 1.0% (4/408) 1.6% (3/193) 1.9% (4/215)
Scott et al43 1970–1990 5.4% (3/56) 0.0% (0/56) 11.1% (3/27) 0.0% (0/27) 10.0% (3/30) 0.0% (0/30)
Shields et al20 1995–1999 0.5% (1/214) 0.0% (0/214) 0.9% (1/112) 0.0% (0/112) 0.9% (1/117) 0.0% (0/117)
The number of trilateral retinoblastoma patients divided by the size of the retinoblastoma cohort in parentheses.
aDuncan et al33 reported that 83 had hereditary retinoblastoma, excluding the 2 pineal trilateral retinoblastoma cases that can be classified as
having hereditary retinoblastoma on the basis of developing a midline primitive neuroectodermal tumor (they also presented a case with an
‘‘orbital midline primitive neuroectodermal tumor,’’ but we are not convinced this is trilateral retinoblastoma).(6/97) chance to develop trilateral retinoblastoma (5 pi-
neal and 1 suprasellar); excluding the suprasellar tumor
from the calculation resulted in a pineal trilateral retino-
blastoma incidence of 5.2% (5/97).22 Finally, in a single-
center study with 5 cases a pineal trilateral retinoblastoma
incidence of 5.7% (5/87) in patients with irradiated hered-
itary retinoblastoma was reported.23
 RISK OF BIAS AND STUDY QUALITY ASSESSMENT: Per-
study scores on individual items of the risk-of-bias checklist
(numbered from Q1 through Q6) can be found in
Supplemental Table 2 (available at AJO.com), showing
considerable risk of bias in terms of how much the cohort
is population-like (Q1 and Q2) and the follow-up duration
(Q4). To address assessment bias we compared trilateral
retinoblastoma incidence in developed vs developing
countries—the latter being potentially more prone to this
type of bias, which would result in lower expected inci-
dence numbers. This comparison indeed showed differ-
ences with unadjusted unilateral and bilateral trilateral
retinoblastoma incidences of 2.3% (95% CI 1.6%–3.2%)
vs 1.1% (95% CI 0.5%–1.9%; P ¼ .32) and bilateral trilat-
eral retinoblastoma incidences of 6.0% (95% CI 3.5%–
9.2%) vs 2.6% (95%CI 0.4%–6.2%; P¼ .50) for developed1122 AMERICAN JOURNAL OFand developing countries, respectively, though statistically
not significantly different.DISCUSSION
THIS SYSTEMATIC REVIEW GIVES AN OVERVIEW OF STUDIES
on trilateral retinoblastoma incidence. Our summary esti-
mates (especially the adjusted ones) of trilateral retinoblas-
toma incidence in bilateral or hereditary retinoblastoma
are considerably lower than previously summarized by
Kivela¨,2 with an estimated incidence ranging from 5% to
15% in bilateral retinoblastoma, reflecting small cohorts
in earlier studies. Even the unadjusted trilateral retinoblas-
toma incidence from this meta-analysis is lower and more
precise (relatively narrow confidence intervals) than
generally assumed in ‘‘literature’’; to test this we evaluated
the trilateral retinoblastoma incidence mentioned in the
introduction and discussion of articles included in the
meta-analysis on survival after trilateral retinoblastoma3
(for obvious reasons, we excluded articles that assessed
trilateral retinoblastoma incidence) (Supplemental
Table 3, available at AJO.com).DECEMBER 2015OPHTHALMOLOGY
TABLE 3. The Incidence of Trilateral Retinoblastoma Among Unilateral and Bilateral Retinoblastoma, Bilateral Retinoblastoma, and
Hereditary Retinoblastoma for Studies That Assessed the Effect of Previous Chemotherapy or Radiotherapy on the Development of
Trilateral Retinoblastoma
Study Inclusion Period
Treatment for
Retinoblastoma
Unilateral and Bilateral Retinoblastoma Bilateral Retinoblastoma Hereditary Retinoblastoma
Pineal Nonpineal Pineal Nonpineal Pineal Nonpineal
Bartuma et al29 2001–2011 Systemic
chemotherapy
0.0% (0/24)a 0.0% (0/24)a
Chantada et al10 1988–2009 Systemic
chemotherapy
1.9% (3/159) 0.0% (0/159)
No systemic
chemotherapy
0.0% (0/38) 0.0% (0/38)
Klufas et al24 2006–2010 Intraarterial
chemotherapy
1.1% (1/89) 0.0% (0/89) 1.4% (1/70) 0.0% (0/70)
Ramasubramania
et al8,21
2000–2012 Systemic
chemotherapy
0.4% (1/252) 0.6% (1/180)
No systemic
chemotherapy
1.9% (3/156) 8.6% (3/35)
Shields et al20 1995–1999 Systemic
chemotherapy
0.0% (0/142) 0.0% (0/142) 0.0% (0/95) 0.0% (0/95) 0.0% (0/99) 0.0% (0/99)
No systemic
chemotherapy
1.4% (1/72) 0.0% (0/72) 5.9% (1/17) 0.0% (0/17) 5.6% (1/18) 0.0% (0/18)
Blach et al22 1979–1990 Radiotherapy 4.3% (5/117) 0.9% (1/117) 5.2% (5/97) 1.0% (1/97)
Imhof et al23 1971–1993 Radiotherapy 4.7% (5/106) 0.0% (0/106) 5.7% (5/87) 0.0% (0/87)
Ramasubramanian
et al8,21
2000–2012 Radiotherapy 2.8% (1/87)
No radiotherapy 1.7% (3/179)
The number of trilateral retinoblastoma patients divided by the size of the retinoblastoma cohort in parentheses.
aTwenty-four patients received a full course of systemic chemotherapy, 1 was previously treated elsewhere, and 2 did not receive (a full
course of) chemotherapy; 1 of these latter 2 patients did develop trilateral retinoblastoma (location unspecified).The lower estimates for trilateral retinoblastoma inci-
dence we calculated potentially reduce the cost-
effectiveness of screening for trilateral retinoblastoma in
patients with retinoblastoma beyond baseline imaging.
More than 50% of trilateral retinoblastomas are diagnosed
at the time of retinoblastoma diagnosis (with baseline mag-
netic resonance imaging of the eyes and brain), suggesting
that baseline screening for trilateral retinoblastoma might
indeed be useful.3
The few studies that published on prior use of systemic
chemotherapy and risk of developing trilateral retinoblas-
toma have shown conflicting results with respect to a po-
tential decrease of trilateral retinoblastoma risk in
patients with retinoblastoma. Whether intraarterial
chemotherapy has an effect on the risk to develop trilat-
eral retinoblastoma—theoretically improbable because
systemic exposure to chemotherapy is very low—was
only assessed in 1 relatively small cohort of 89 patients
and does not allow for any conclusions on this issue.24
Also, the few studies that looked at prior radiotherapy
did not allow for any meaningful meta-analysis. Should
previous radiotherapy (commonly used before the year
1995) be inductive and previous chemotherapy (increas-
ingly used since the year 1995) protective, then we wouldVOL. 160, NO. 6 THE INCIDENCE OF TRILATEexpect to see a clear reduction of trilateral retinoblastoma
incidence over time. The estimated incidences did
slightly decrease after the year 1995, but the differences
were not statistically significant (Figure 3). Alternatively,
larger cohort sizes in later studies could partially explain
this difference.
There is much heterogeneity between the studies report-
ing trilateral retinoblastoma incidence. Some studies
looked at incidence data in a population (3 cohorts from
3 studies; see Table 1), but most are data from 1 or more
(specialized) institutions, which—owing to referral bias—
might have resulted in a higher trilateral retinoblastoma
incidence, or maybe actually a lower incidence when chil-
dren with trilateral retinoblastoma end up in different
specialized pediatric neurooncology centers (Table 2).
Also, some of the cohorts are from the same center. Other
potential sources of heterogeneity are the choice of start
date and end date (year) of the retinoblastoma cohort at
risk, and loss to follow-up of patients in the cohort. The es-
timates in this study assume that of all patients with retino-
blastoma in the cohort it is known whether they developed
trilateral retinoblastoma, which might be considered
appropriate because trilateral retinoblastoma develops rela-
tively quickly (median interval 17 months) after1123RAL RETINOBLASTOMA
FIGURE 3. Forest plots of trilateral retinoblastoma incidence in cohorts of patients with (Top) unilateral and bilateral, (Middle)
bilateral, and (Bottom) hereditary retinoblastoma. Incidence in percentages with a 95% confidence interval in parentheses.
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retinoblastoma (since 1995 >95% are diagnosed with
trilateral retinoblastoma before the age of 5 years).3
There is a risk that patients with asymptomatic trilateral
retinoblastoma without histopathologic proof of disease
might have been false-positive trilateral retinoblastoma
cases (eg, benign pineal cysts25), causing an overestimation
of trilateral retinoblastoma incidence. On the other hand,
patients with retinoblastoma, especially those from severalVOL. 160, NO. 6 THE INCIDENCE OF TRILATEdecades back, might have died from central nervous system
metastases that were not recognized as trilateral retinoblas-
toma (ie, false negatives).
In summary the incidence of trilateral retinoblastoma
is estimated to be substantially lower than previously re-
ported in the literature concerning trilateral retinoblas-
toma, especially after adjusting for bias from small
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SUPPLEMENTAL TABLE 1. The Syntaxes Used to Obtain Articles That Reported Incidence of Trilateral RetinoblastomaWith Pubmed
and Embase
Pubmed search syntaxa:
(‘‘Retinoblastoma’’[Mesh] OR retinoblastoma[tw] OR retinoma[tw] OR retinocytoma[tw]) AND (‘‘Pinealoma’’[Mesh] OR pinealoma[tw] OR
pineoblastoma[tw] OR pinealoblastoma[tw] OR pineal[tw] OR trilateral[tw] OR ectopic[tw] OR brain[tw] OR sellar[tw] OR suprasellar[tw] OR
parasellar[tw]) AND ((‘‘1966/01/01’’[PDAT] : ‘‘3000/12/31’’[PDAT]) AND (Dutch[lang] OR English[lang] OR German[lang])) NOT
(‘‘Animals’’[Mesh] NOT ‘‘Humans’’[Mesh])
The Embase search syntaxa:
(‘retinoblastoma’ OR ‘retinoblastoma’/exp OR retinoblastoma OR ‘retinoma’ OR ‘retinoma’/exp OR retinoma OR ‘retinocytoma’ OR
‘retinocytoma’/exp OR retinocytoma) AND (‘pinealoma’ OR ‘pinealoma’/exp OR pinealoma OR pineoblastoma OR ‘pinealoblastoma’ OR
‘pinealoblastoma’/exp OR pinealoblastoma ORpineal OR trilateral OR ectopic OR ‘brain’ OR ‘brain’/exp OR brain OR sellar OR suprasellar
OR parasellar) AND [humans]/lim AND [embase]/lim AND ([dutch]/lim OR [english]/lim OR [german]/lim) AND [medline]/lim AND [1966–
2015]/py
aBoth searches were performed on March 14, 2014 and updated on July 15, 2015.1126.e2 DECEMBER 2015AMERICAN JOURNAL OF OPHTHALMOLOGY
SUPPLEMENTAL TABLE 2. Risk-of-Bias Assessment With
a Modified Checklist by Hoy and Associates17 of the Studies
That Assessed the Incidence of Trilateral Retinoblastoma
and Were Included in This Systematic Review and Meta-
analysis
Author Q1 Q2 Q3 Q4 Q5 Q6
Amoaku et al26 1 2 2 0 2 1
Antoneli et al27 2 0 2 2 2 1
Azar et al28 2 0 2 0 0 0
Bartuma et al29 0 0 0 1 2 0
Blach et al22 0 0 0 2 2 1
Chantada et al10 0 2 2 0 1
De Ioris et al31 2 0 2 0 2 1
De Potter et al32 0 0 2 0 2 1
Duncan et al33 1 0 2 1 2 1
Helveston et al34 2 0 2 0 2 1
Imhof et al23 0 0 2 2 2 1
Jubran et al35 0 0 2 0 2 1
Jurkiewicz et al36 0 0 2 0 0 1
Kingston et al37 0 0 2 0 2 1
Klufas et al24 0 0 0 0 2 0
Lim et al38 0 0 2 0 2 1
Lim et al39 0 0 2 1 2 1
Lueder et al40 0 0 2 0 2 1
Lueder et al41 0 0 2 0 2 1
Moll et al6 2 2 2 2 1
Moreno et al30 0 2 2 0 2 1
Popovic et al25 0 0 0 0 2 1
Provenzale et al42 0 0 2 0 2 1
Ramasubramanian et al8,21 0 0 0 0 2 1
Scott et al43 0 0 2 0 2 1
Shields et al20 0 0 2 0 2 0
0 ¼ high risk, 1 ¼ intermediate risk, 2 ¼ low risk.
Q1. Was the study’s target population a close representation of the
national population in relation to relevant variables? (Based on
Marees et al.,18,19 ie, 39.4% bilateral cases)
0 points: proportion of bilateral deviates considerably (>_6 percent-
age points [%pts]) from population-like or undefined.
1 point: proportion of bilateral deviates slightly (3–6 %pts) from
population-like.
2 points: proportion of bilateral population-like (<3 %pts).
Q2. Was the sampling frame a true or close representation of the
target population? (eg, hospital-based: high risk, population-
based: low risk)?
0 points: hospital-based or undefined.
2 point: national or regional population.
Q3. Was some form of random selection used to select the sample,
OR was a census undertaken?
0 points: selected cases (eg, based on type of therapy or unde-
fined).
2 points: consecutive cases.
Q4. Was the likelihood of patients missing from follow-up minimal?
Was the length of the shortest prevalence period for the parameter
of interest appropriate? (ie, adequate length of follow-up to observe
the outcome)
0 points: median follow-up <2.5 years or undefined.
1 point: median follow-up >_2.5 but <5 years.
2 points: median follow-up >_5 years.
Q5. Was an acceptable case definition used in the study?
0 points: temporal clustering of cases with increasing follow-up or
unclear.
2 points: no evidence of temporal clustering of cases with
increasing time period.
Q6.Was the way of trilateral retinoblastoma assessment appropriate
(eg, histopathology, cerebrospinal fluid and on imaging: treatment
response to therapy or disease progression)?
0 points: undefined.
1 point: clinical diagnosis including imaging.
2 points: based on histopathology.
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SUPPLEMENTAL TABLE 3. Trilateral Retinoblastoma Incidence Mentioned in the Introduction or Discussion of Articles Since 2000
Included in our Meta-analysis on Trilateral Retinoblastoma Survival,1 Excluding Articles That Assessed Trilateral Retinoblastoma
Incidence
Study Year Retinoblastoma Population
Incidence of Trilateral
Retinoblastoma Source According to Authors
Bonci et al2 2013 Bilateral 8%–10% Kivela¨3
Dai et al4 2008 Unilateral or bilateral 3% Bader et al,5 Amoaku et al,6 De Potter et al,7 Pesin et al8
Dimaras et al9 2011 Unilateral or bilateral 3% De Potter et al7
D’Elia et al10 2014 Sporadic unilateral <0.5% De Potter et al7
Sporadic bilateral 5%–13%
Familial bilateral 5%–15%
Dunkel et al11 2010 Bilateral 6% Blach et al12
Huddleston et al13 2013 Genetic form 3%–9% Blach et al,12 Shields et al14
Ibarra et al15 2000 Unilateral 0.5% Kingston et al,16 De Potter et al,7 Blach et al12
Bilateral 4%–10%
James et al17 2010 Unilateral or bilateral 1.5%–5% Provenzale et al18
Kamaleshwaran et al19 2014 Sporadic unilateral <0.5% Kivela¨3
Sporadic bilateral 5%–13%
Familial bilateral 5%–15%
Kivela et al20 2003 Hereditary 5%–15% Kivela¨,3 Kingston et al,16 Blach et al,12 De Potter et al7
Raizis et al21 2013 Unspecified <1% Antoneli et al22
Rodjan et al23 2012 Sporadic unilateral <0.5% De Potter et al,7 Kivela¨3
Sporadic bilateral 5%–13%
Familial bilateral 5%–15%
Popovic et al24 2006 Unspecified 4%–8% Kingston et al,16 De Potter et al,7 Shields et al25
Popovic et al26 2007 Sporadic unilateral <0.5% Kivela¨3
Sporadic bilateral 5%–13%
Familial bilateral 5%–15%
Shah et al27 2013 All 3% Shields et al28
Unilateral 0.5%
Bilateral 2%–11%
Skrypnyk et al29 2004 Unspecified 5% De Potter et al7
Tsuruta et al30 2011 All 3% De Potter et al7
Wright et al31 2010 Genetic form 3%–9% Blach et al12
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